MONITORING FOR ALL PATIENTS AT FIRST ANC VISIT TB screening and sputum Gene Expert TB diagnosed: start TB Rx. If on ART, continue. If not yet on ART: see algorithm on centre spread To identify TB suspects and assess TPT **TB excluded:** start ART. If CD4 > 350, defer TPT until 6 weeks postpartum. If CD4 ≤ 350, initiate TPT for 12 months eligibility CrAg (cryptococcal antigen), If CrAg-positive: refer for urgent LP and patient should be discussed with an expert. Fluconazole is teratogenic. Defer ART if ART-naïve, but if CD4 ≤ 100 To treat or provide prophylaxis for don't stop ART if already on ART cryptococcal meningitis If CrAg-negative: start or continue ART Screen for chronic diseases Treat according to relevant guidelines To identify high risk pregnancy **Nutritional assessment** All pregnant women should get calcium, folate and iron To detect deficiency and provide necessary supplementation. Be aware that DTG interacts with some medicines: nutritional support refer to PMTCT guideline p17. Women with BMI < 23: refer to dietician Provide counselling for safer sex, post-natal contraception and partner **Family planning** testing If RPR done before 20 weeks and negative: repeat RPR at 32 weeks. STI and syphilis screening (RPR) Treat all women with a positive syphilis screening test irrespective of To identify and treat STIs titre: refer to PMTCT guideline p11 Viral load, if on ART See algorithm on centre spread. To identify treatment failure Be sure to check results and respond quickly! Hb or FBC Treat according to relevant guidelines To detect anaemia and/or neutropaenia Mental health screening Treat according to relevant guidelines To identify mental health issues HBsAg**, if unknown If HBsAg-positive: include TDF in regimen. Provide post-exposure To assess HBV status prophylaxis of hepatitis B for infant as per relevant guidelines

⁵ If the client has recently had TB, the GXP may give a false-positive. Please call an expert or the hotline to discuss; "If HBsAg negative and not immune, provide Hep B vaccination as per National Viral Hepatitis guidelines. Hep B vaccination is not contraindicated in pregnancy. If high-risk and status unknown at delivery, test.

MONITORING AT MONTHLY ANC VISITS: PATIENTS ON ART			
TEST AND PURPOSE	TIMING AND RESPONSE		
Viral load To confirm viral suppression or detect virological failure timeously	Refer to VL algorithm on previous page		
CD4 count To assess immunological status, risk of OIs and need for prophylaxis	At 12 months on ART. Thereafter, repeat every 6 months until client meets criteria to discontinue CPT Stop CD4 monitoring if client's VL remains < 1000 c/mL. If VL > 1000 c/mL, monitor CD4 count every 6 months		
TB symptom screening To identify TB suspects and assess TPT eligibility	Every clinic visit		
FBC, if on AZT To detect anaemia and/or neutropaenia	At initiation, month 3, month 6, then annually		
s-Creatinine [™] , if on TDF To assess renal function and eligibility for TDF	At initiation, month 3, month 6, month 12 and then annually. If s-Creatinine [™] > 85 μmol/L: do not use TDF. See front page		

Please note: calculated eGFR is not accurate during pregnancy. Serum creatinine and <u>not</u>eGFR should be used

BREASTFEEDING

- Breastfeeding should be initiated within one hour of delivery
- Exclusive breastfeeding for first 6 months of life
- If mother is suppressed on ART, mixed feeding is not a reason to stop breastfeeding
- Introduction of age-appropriate solids from 6 months onwards
- Continue breastfeeding until 2 years of age or older
- Ensure mother is on ART, adherent and VL is suppressed
- It is recommended that women with a VL ≥ 1000 c/mL on first-line ART continue to breastfeed. Infant prophylaxis should be extended/restarted while a concerted effort is made to re-suppress the mother's VL
- Stopping breastfeeding should be done slowly, over a month
- Breastfeeding should be avoided in mothers who are failing second- or third-line

WHAT DOES EXCLUSIVE BREASTFEEDING MEAN?

For the first six months of life, the baby only gets mother's milk and medication. This means no water, formula, other foods or fluids

3TC = lamivudine; ABC = abacavir; ART = antiretroviral treatment; ATV/r = atazanavir/ritonavir; AZT = zidovudine; CPT = cotrimoxazole preventive therapy; CrAg = cryptococcal antigen; DTG = dolutegravir; EFV = efavirenz; FTC = emtricitabine; GXP = Gene Expert TB test; Hb = haemoglobin; HCT = HIV counselling and testing; HIV = human immunodeficiency virus; IRIS = immune reconstitution syndrome; LP = lumbar puncture; LPV/r = lopinavir/ritonavir; MTCT = mother to child transfer; NTD = neural tube defect; NVP = nevirapine; OI = opportunistic infections; PCR = polymerase chain reaction; PICT = provider-initiated counselling and testing; PMTCT = prevention of mother to child transfer; LTFU = lost to follow-up; RTHB = road to health booklet; Rx = treatment; sCr = serum creatinine; STI = sexually transmitted infections; TDF = tenofovir; TEE = tenofovir + emtricitabine + efavirenz; TLD = tenofovir + lamivudine + dolutegravir; TPT = tuberculosis preventive therapy; VL = viral load; WOCP = woman of childbearing potential

PMTCT FOR MOTHERS 2019

First version April 202

RECOMMENDED REGIMENS

TLD is the preferred regimen in pregnant women, after 6 weeks of completed gestation (4 weeks post-conception), and in women who are not actively trying to conceive.

In order to make an informed choice between a DTG- or EFV-based regimen, provide the mother with all the necessary information, including the potential risk of NTDs and contraceptive choices

UNBOOKED/PRESENTS IN LABOUR

Women not on ART, who	Stat dose of TLD + NVP. Start life-	Check s-Creatinine [™] and CD4. Review results
test HIV-positive in labour	long ART the next day	at 3-6 day visit and adapt ART accordingly

^wPlease note: calculated eGFR is not accurate during pregnancy. Serum creatinine and <u>not</u> eGFR should be used

FIRST-LINE ART FOR PREGNANT AND BREASTFEEDING WOMAN (> 6 WEEKS OF PREGNANCY OR 4 WEEKS POST-CONCEPTION)

If a pregnant woman presents to the clinic before 6 weeks of pregnancy (4 weeks post-conception), contact the HIV hotline

		Preferred regimen	
ART-naïve		TLD* (refer to algorithm on next page)	Keeping the
Contra-indications	Renal disease (sCr > 85)	ABC/AZT + 3TC + DTG [*]	mom's VL
to TDF	Weight < 35 kg	ABC + 3TC + DTG [*]	suppressed is the best way
Already on TEE	VL < 50 within last 6 months	Offer switch to TLD*	to protect
Already on TEE	VL > 50 within last 6 months	See VL algorithm on the next page	her infant
Not currently on ART and previously on TEE e.g. PMTCT or LTFU on ART If previous ART was not TEE, contact hotline		VL < 50 while on TEE: TLD* Unsuppressed VL or no documented VL while previously on ART: AZT + 3TC + DTG*	

^{*}Before DTG initiation, all women and adolescent girls of childbearing potential must be appropriately counselled on the potential risk of NTDs with DTG use around conception and within the first 6 weeks of pregnancy (4 weeks post-conception). They should be provided with their choice of contraception if not pregnant

SECOND-LINE ART FOR PREGNANT/BREASTFEEDING WOMEN

If HBV status unknown, check HBsAa

y a control animicantly circuit is				
Current failing regimen	Second-line regimen			
	HBsAg negative	HBsAg positive		
TDF + 3TC/FTC + EFV/NVP	AZT + 3TC/FTC + DTG	AZT + TLD		
	If DTG not suitable ^α :	If DTG not suitable ^α :		
	AZT + 3TC/FTV + LPV/r	TDF + 3TC/FTC + LPV/r		
TLD (> 2 years)	AZT + 3TC/FTV + LPV/r	TDF + 3TC/FTC + LPV/r		
AZT/TDF + 3TC/FTC + LPV/r or ATV/r (> 2 years)	No PI resistance: continue ART, address adherence. If intolerance to LPV/r is affecting adherence, discuss substitutions with hotline or expert PI resistance: refer to 3 rd line committee			

^αDTG should not be used within the first 6 weeks of pregnancy. Women can make an informed choice to use or not use DTG

NEED HELP?

Contact the TOLL-FREE National HIV & TB Health Care Worker Hotline

0800 212 506 /021 406 6782

Alternatively "WhatsApp" or send an SMS or "Please Call Me to 071 840 1572 www.mic.uct.ac.za







ICINES
REMATION
REFERENCE
Based on the Guideline for the Prevention
of Mother to Child Transmission of
Communicable Infections . National
Department of Health, South Africa. 2019

This publication was supported under funding provided by the Global Fund to Fight AIDS, Tuberculosis and Malaria through the National Department of Health of South Africa and the NDoH Pharmacovigilance Centre for Public Health Programmes. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Global Fund or the National Department of Health of South Africa

